InSilico Medicine Announces Key Phase I Data for ISM6331 Accepted for Rapid Oral Presentation at ESMO 2026
Key Highlights for Investors
- First-in-human Phase I data for ISM6331, an AI-driven pan-TEAD inhibitor, accepted for Rapid Oral Presentation at ESMO Congress 2026.
- ISM6331 is a novel therapy targeting mesothelioma and other advanced solid tumors.
- Phase I trial data to be presented on October 25, 2026 in Madrid, Spain.
- Orphan Drug Designation (ODD) granted by the U.S. FDA for mesothelioma in August 2024.
- First patient dosed in January 2025 in a global multicenter trial (China & US).
- ISM6331 is designed using InSilico’s proprietary AI platform Chemistry42, highlighting its innovation leadership.
Detailed Article
Hong Kong, July 27, 2026 — InSilico Medicine Cayman TopCo (HKEX: 3696) has announced a significant milestone for its novel cancer therapy, ISM6331. The company’s first-in-human Phase I clinical trial data for ISM6331, a cutting-edge AI-designed pan-TEAD inhibitor, has been accepted for a prestigious Rapid Oral Presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026, set to take place October 23-27, 2026, in Madrid, Spain. The data will be presented on October 25, 2026 (08:30-10:00 a.m. CEST) in the Cordoba Auditorium, Hall 4.
About the Phase I Clinical Trial
The Phase I clinical study is a first-in-human, multicenter trial conducted simultaneously in China and the United States. It was designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ISM6331 as a single agent in patients with advanced or metastatic malignant mesothelioma and other solid tumors. The acceptance of this data for a Rapid Oral session at ESMO is a strong indicator of the potential significance of the findings for the oncology community and investors.
About ISM6331
ISM6331 is a potent, non-covalent, pan-TEAD inhibitor developed using InSilico’s proprietary AI-driven platform, Chemistry42. This molecule is designed to target tumors with abnormalities in the Hippo pathway, a pathway implicated in cancer development and progression. Preclinical studies have shown ISM6331 offers broad anti-tumor efficacy, high potency at low doses, and a favorable safety and ADMET profile. Notably, the compound also exhibits synergistic effects and the ability to overcome drug resistance when used in combination therapies.
In August 2024, ISM6331 was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of mesothelioma, providing potential regulatory and commercial advantages. The first patient was dosed in January 2025 in the ongoing global Phase I study.
Potential Impact on Shareholders and Share Price
- The acceptance of Phase I data for a Rapid Oral presentation at ESMO suggests that ISM6331’s clinical results are both promising and of high interest to the oncology community. This could drive increased investor confidence and potentially impact the share price positively.
- The Orphan Drug Designation from the FDA for mesothelioma is another price-sensitive development, as it may lead to market exclusivity and expedited development pathways in the U.S.
- InSilico’s leadership in AI-driven drug discovery and the successful transition of its pipeline from preclinical to clinical stages further validates its business model and technology platform.
Investors should note, however, that these results are early-phase clinical data. While the acceptance for a major congress presentation is positive, further data (including efficacy and safety from later-phase studies) will be required to confirm ISM6331’s potential commercial viability.
Corporate Governance
The announcement was made by Dr. Aleksandrs Zavoronkovs, Chairman, Executive Director, CEO, and CBO of InSilico Medicine. The Board comprises a mix of executive, non-executive, and independent non-executive directors with deep scientific and industry expertise.
Disclaimer
This article is based on a company announcement and contains forward-looking statements subject to risks and uncertainties. The Company’s financial data disclosed have not been audited or reviewed by its auditors. Shareholders and potential investors should exercise caution and seek professional advice before making any investment decisions.
